Search clinical trials for: Riociguat (BAY63-2521)

Total 333 results

Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Bayer

Completed

Interaction With HIV Antiretroviral Agents

HIV-DDI

United States
Bayer

Completed

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy (REGARD)

Colorectal Neoplasms

Turkey
Bayer

Completed

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Neoplasms

Canada, United States
Bayer

Completed

Regorafenib Phase I Study in Mainland Chinese Patients

Oncology

China
Bayer

Completed

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CONCUR)

Colorectal Neoplasms

China, Hong Kong, Taiwan, Vietnam, Korea, Republic of
Bayer

Completed

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Neoplasms

Hong Kong, Singapore
Bayer

Completed

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Tumors

Japan
Bayer

Completed

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Colorectal Neoplasms

Germany
Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Bayer

Completed

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Atrial Fibrillation

Germany
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
Actelion

Completed

Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics

Healthy Subjects

Germany
Bayer

Completed

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Metastatic Colorectal Cancer

India
Bayer

Completed

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Bayer

Active, not recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

France, Japan, Taiwan, Korea, Republic of, Spain
Bayer

Completed

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (COLONGER)

Metastatic Colorectal Cancer

United States
Bayer

Completed

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Carcinoma, Renal Cell

United States, France, United Kingdom, Finland, Germany, Poland
Bayer

Completed

Regorafenib Post-marketing Surveillance

Colorectal Neoplasms

Japan
Bayer

Completed

Safety and Effectiveness of Regorafenib (Correlate)

Neoplasms

Austria, Czechia, Switzerland, Italy, France, Mexico, Singapore, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Argentina
Bayer

Completed

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Neoplasms

United States
MediciNova

Completed

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
University of Colorado, Denver
Bayer

Recruiting

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Chronic Thromboembolic Disease (CTED) | Exercise Intolerance Post PEA Surgery

United States
Bayer

Completed

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Colorectal Neoplasms

Korea, Republic of
Bayer

Completed

Regorafenib Post-marketing Surveillance in Japan

Gastrointestinal Stromal Tumors

Japan
Bayer

Completed

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer (REGO-ACT)

Colorectal Neoplasms

Austria
Bayer

Completed

Stivarga Real Life Evidence in Hungary

Colorectal Neoplasms

Hungary
Bayer

Completed

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics | Dietary Fats

United States
A2A Pharmaceuticals Inc.

Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Triple Negative Breast Cancer | Endometrial Cancer | High Grade Serous Ovarian Cancer

United States
Humanity & Health Medical Group Limited

Recruiting

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Hepatocellular Carcinoma

Hong Kong
Mark Gladwin

Completed

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

Sickle Cell Disease

United States
Medical University of Vienna

Completed

Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (DYNAMIC)

Hypertension, Pulmonary | Heart Failure With Normal Ejection Fraction

Austria
University of Cincinnati

Unknown

Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RioSAPH)

Sarcoidosis

United States
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Chronic Spontaneous Urticaria
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Australia, Spain, Italy
Ronald M Burch MD PhD

Completed

Safety and Tolerability of GATE-251 in Normal Human Volunteers

Major Depressive Disorder
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Dinesh Khanna, MD, MS
Bayer

Completed

Riociguat in Scleroderma Associated Digital Ulcers (RESCUE)

Scleroderma | Digital Ulcers

United States
Therapex Co., Ltd

Not yet recruiting

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Carcinoma, Non-Small-Cell Lung | EGFR Mutant Advanced Non-Small Cell Lung Cancer
Zeria Pharmaceutical

Completed

Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Primary Hypophosphatemic Rickets

Japan
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Bayer

Completed

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib (COLONG)

Colorectal Neoplasms

Belgium
Bayer

Terminated

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes? (SMART)

Physician Education

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Richard Moon

Completed

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

Altitude Sickness | Hypertension, Pulmonary

United States
Bayer

Terminated

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Neoplasms

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France

3

Subscribe